Summary
Goodwin Procter is a sponsor of the quarterly Nature Biotech SciCafe series. This invitation-only event features presentations from local researchers to biotech executives and VCs.
Related Content
- PublicationOctober 2, 2023
FDA Proposes Phased Approach to Regulating Laboratory Developed Tests
- Big Molecule WatchSeptember 29, 2023
Regulatory Update on Alvotech’s AVT02, a High-Concentration Interchangeable Adalimumab Biosimilar
- Big Molecule WatchSeptember 29, 2023
FDA Grants Priority Review to Merck’s Application for KEYTRUDA (pembrolizumab) as Part of Treatment for Early-Stage Cervical Cancer
- Life Sciences PerspectivesSeptember 29, 2023
FDA Proposes Phased Approach to Regulating Laboratory Developed Tests
- InsightSeptember 29, 2023
A Look Ahead in Life Sciences: What We Are Tracking in Q4 2023 and Beyond
- Big Molecule WatchSeptember 28, 2023
Recent Biosimilar Commercialization Developments
- Life Sciences PerspectivesSeptember 28, 2023
Bloomberg Intelligence – Arman Oruc’s Perspective on the FTC and Pharma and Biotech Industry M&A Impact
- Big Molecule WatchSeptember 27, 2023
Scheduling Order Issued in REGENXBIO v. Sarepta Litigation
- Press ReleaseOctober 2, 2023
Goodwin Names 40 New Partners
- Awards and RankingsOctober 2, 2023
Matt Wetzel Named the 2023 Patricia T. Meador Leadership Award Recipient by the American Health Law Association
- Press ReleaseOctober 2, 2023
Goodwin Expands Life Sciences Practice with Capital Markets Partner Adam Johnson in New York
- In the PressSeptember 28, 2023
FemHealth Ventures Closes $32 Million Fund for Women’s Health Investments (The Wall Street Journal)
- Press ReleaseSeptember 27, 2023
Acino Significantly Expands Presence and Capabilities in Latin America Through Acquisition of M8 Pharmaceuticals
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Press ReleaseSeptember 22, 2023
Aditum Bio Announces Formation of Celexor Bio, Focused on Cell Depletion of Pathologic Cells in Autoimmune and Inflammatory Disorders
- Press ReleaseSeptember 22, 2023
Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines